JPWO2020247814A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020247814A5 JPWO2020247814A5 JP2021572301A JP2021572301A JPWO2020247814A5 JP WO2020247814 A5 JPWO2020247814 A5 JP WO2020247814A5 JP 2021572301 A JP2021572301 A JP 2021572301A JP 2021572301 A JP2021572301 A JP 2021572301A JP WO2020247814 A5 JPWO2020247814 A5 JP WO2020247814A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- cells
- mol
- optionally
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857587P | 2019-06-05 | 2019-06-05 | |
| US62/857,587 | 2019-06-05 | ||
| PCT/US2020/036415 WO2020247814A1 (en) | 2019-06-05 | 2020-06-05 | Compositions and methods for modifying eukaryotic cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022534798A JP2022534798A (ja) | 2022-08-03 |
| JPWO2020247814A5 true JPWO2020247814A5 (de) | 2023-06-13 |
Family
ID=73652293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572301A Pending JP2022534798A (ja) | 2019-06-05 | 2020-06-05 | 真核細胞を修飾するための組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230002784A1 (de) |
| EP (1) | EP3980549A4 (de) |
| JP (1) | JP2022534798A (de) |
| CN (1) | CN114450412A (de) |
| WO (1) | WO2020247814A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021202658A1 (en) | 2021-04-28 | 2022-11-17 | Fondazione Telethon | Gene therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000041732A1 (en) * | 1999-01-19 | 2000-07-20 | The Children's Hospital Of Philadelphia | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
| CA2401239A1 (en) * | 2000-03-03 | 2001-09-13 | Valentis, Inc. | Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| DK2820138T3 (da) * | 2012-02-29 | 2020-12-07 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Retroviral transduktion under anvendelse af poloxamerer |
| IL257939B2 (en) * | 2015-09-24 | 2023-03-01 | Biomarin Pharm Inc | Adeno-associated virus factor 8 vectors, associated virus particles, and medicinal formulations comprising the same |
| CA3014078A1 (en) * | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| JP7228523B2 (ja) * | 2017-03-29 | 2023-02-24 | ブルーバード バイオ， インコーポレイテッド | ヘモグロビン異常症を治療するためのベクターおよび組成物 |
-
2020
- 2020-06-05 CN CN202080055828.0A patent/CN114450412A/zh active Pending
- 2020-06-05 WO PCT/US2020/036415 patent/WO2020247814A1/en unknown
- 2020-06-05 US US17/615,773 patent/US20230002784A1/en active Pending
- 2020-06-05 JP JP2021572301A patent/JP2022534798A/ja active Pending
- 2020-06-05 EP EP20818531.4A patent/EP3980549A4/de active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2348868T3 (es) | Vectores retrovirales terapeuticos para terapia genica. | |
| JP2019504635A (ja) | Ｖｃｎエンハンサー組成物およびその使用方法 | |
| Dornadula et al. | HIV-1 virions produced from replicating peripheral blood lymphocytes are more infectious than those from nonproliferating macrophages due to higher levels of intravirion reverse transcripts: implications for pathogenesis and transmission | |
| WO2011008348A2 (en) | Dual vector for inhibition of human immunodeficiency virus | |
| CA2298892A1 (en) | Lentiviral vectors derived from sivagm, methods for their preparation and their use for gene transfer into mammalian cells | |
| WO1997048815A2 (en) | Method for enhancing gene transfer | |
| JP2001513643A (ja) | レンチウイルスをベースとするベクター及びベクター系 | |
| US8557573B2 (en) | Vector particles for targeting CD34+ cells | |
| Gervaix et al. | Gene therapy targeting peripheral blood CD34+ hematopoietic stem cells of HIV-infected individuals | |
| US20180127470A1 (en) | Cell Lines | |
| WO2021076993A1 (en) | Compositions and methods for modifying eukaryotic cells | |
| JPWO2020247814A5 (de) | ||
| JPWO2021076993A5 (de) | ||
| US20230002784A1 (en) | Compositions and methods for modifying eukaryotic cells | |
| EP1835032A1 (de) | Selbst-inaktivierender rekombinanter lentiviraler Vektor zur Inhibierung von HIV | |
| AU2022341119A1 (en) | Compositions and methods for treating or preventing autoimmune diseases | |
| Ignatius et al. | The immunodeficiency virus coreceptor, Bonzo/STRL33/TYMSTR, is expressed by macaque and human skin-and blood-derived dendritic cells | |
| AU2004252010A1 (en) | Method for transplanting lymphohematopoietic cells into mammal | |
| WO2023038055A1 (ja) | レトロウイルスベクター製造用の核酸 | |
| Takebe et al. | Protection of Hematopoietic Progenitor Cells from Chemotherapy Toxicity by Transfer of Drug Resistance Genes | |
| CA2289918A1 (en) | Mammalian cell transduction for use in gene therapy | |
| Takao et al. | Unintegrated DNA in cells infected in vitro with human immunodeficiency virus (HIV): a new approach to suppression of virus release | |
| Takebe et al. | MDR-1 8.3. 3 Cytidine Deaminase 8.3. 4 Aldehyde Dehydrogenase Class 1 Dihydrofolate Reductase | |
| KR20230110243A (ko) | 유전성 혈관부종을 치료하거나 예방하기 위한 조성물 및 방법 | |
| Gori | Methotrexate resistance gene transfer in stem cells |